cis-Hydroxyproline-mediated pancreatic carcinoma growth inhibition in mice
- First Online:
- Cite this article as:
- Sturm, D., Maletzki, C., Braun, D. et al. Int J Colorectal Dis (2010) 25: 921. doi:10.1007/s00384-010-0946-1
- 191 Downloads
This study addressed the question of whether the collagen metabolism modulator cis-4-Hydroxy-l-proline (CHP) is applicable for potential use as a therapeutic inhibitor of pancreatic carcinoma cell growth.
Cell proliferation, as well as quantification of apoptosis of murine Panc02 cells, was assessed after CHP treatment. Supplementary, the effect of CHP on tumor growth was examined in the subcutaneous Panc02 model in vivo. Mice received daily intraperitoneal injections of CHP (300, 400, and 500 mg/kg bw). In addition to the assessment of systemic parameters (blood count, enzyme activities), histology (HE) and immunohistochemistry (Ki-67) were performed from resected tumor specimens.
Like reduction of metabolic activity, CHP also induced inhibition of cell growth in a dose-dependent manner, with however only slight increases in apoptosis. In vivo treatment of Panc02 tumors with CHP resulted in pronounced delay of tumor growth and decreases in tumor cell proliferation. Moreover, these effects were accompanied by a massive systemic leukocytosis as well increased leukocyte infiltration into the tumors subsequent to CHP therapy.
CHP inhibits the proliferation of Panc02 tumor cells in a dose-dependent manner both in vitro and in vivo. Our presented data show that modulation of the collagen metabolism is an interesting strategy for treatment of pancreatic carcinoma.
Keywordscis-Hydroxyproline Pancreatic cancer Growth inhibition Mouse model
Peripheral blood leukocytes